Literature DB >> 25791894

Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid.

Monika Kalowska1, Olga Ciepiela, Cezary Kowalewski, Urszula Demkow, Robert A Schwartz, Katarzyna Wozniak.   

Abstract

Bullous pemphigoid (BP) is characterized by IgG and IgE autoantibodies to the NC16a domain of BP180. This study evaluated the correlation between body surface area (BSA), total serum IgE and enzyme-linked immunoassay (ELISA) for IgG and IgE anti-NC16a in 77 patients with BP in the active stage, and the degree of conversion to negative of the studied parameters in clinical remission. Statistically positive correlations were observed between BSA and examined parameters (correlation index 0.2548, 0.2491, 0.311, respectively). Originally, patients with BP with positive ELISAs for both IgG and IgE autoantibodies presented twice as extensive skin lesions as those with positive IgG and negative IgE ELISAs. Conversion of ELISAs for IgG and IgE to negative in clinical remission occurred in 9.3% and 81% of patients with BP, respectively. This confirmed that ELISA for IgE anti-NC16a is a helpful parameter in the modification of current treatment and the assessment of risk of relapse in BP.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25791894     DOI: 10.2340/00015555-2101

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  10 in total

1.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 2.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

Review 3.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 4.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

5.  Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Karolina Gadaldi; Laurence Feldmeyer; Nikhil Yawalkar; Luca Borradori; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

6.  Clinical characteristics of pruritus in patients with bullous pemphigoid: a preliminary questionnaire-based study.

Authors:  Agnieszka Kalinska-Bienias; Emilia Kowalczyk; Pawel Jagielski; Anna Lesniewska; Aleksandra Komorowska; Cezary Kowalewski; Katarzyna Wozniak
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

Review 7.  IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.

Authors:  Ariadne Hadjikyriacou Saniklidou; Patrick J Tighe; Lucy C Fairclough; Ian Todd
Journal:  Arch Dermatol Res       Date:  2017-10-25       Impact factor: 3.017

8.  IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Authors:  P C Freire; C H Muñoz; G Stingl
Journal:  Br J Dermatol       Date:  2017-11-28       Impact factor: 9.302

9.  High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.

Authors:  Hiroshi Koga; Kwesi Teye; Norito Ishii; Chika Ohata; Takekuni Nakama
Journal:  Front Med (Lausanne)       Date:  2018-05-09

Review 10.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.